AVXL 株価推移チャート
AVXL 収入
Anavex Life Sciences Corp
$3.08
0%
$0
終値： May 14, 16:00:00 GMT-4
$3.08
0%
$0
アフターマーケット：May 14, 16:03:34 GMT-4
戻る
Anavex Life Sciences Corp (AVXL) 収入
最新の利益結果: Q1 '26
報告済み: 2026-02-09
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
AVXLの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Anavex Life Sciences Corp AVXLの前四半期の収益はどうでしたか？
Anavex Life Sciences Corpの収益見積もりはいくらですか？
Anavex Life Sciences Corpの収益品質スコアはどれくらいですか？
Anavex Life Sciences Corpはいつ収益を報告しますか？
Anavex Life Sciences Corpの予想収益はいくらですか？
Anavex Life Sciences Corpは収益予想を上回りましたか？
主要データ
前終値
$3.08
始値
$3.07
当日レンジ
$2.94 - $3.13
52週レンジ
$2.61 - $13.99
取引高
1.2M
平均取引高
1.3M
配当利回り
--
1株当たり利益(TTM)
-0.46
時価総額
$285.4M
AVXLとは何ですか？
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.
